Therapy
Female CEOs
Health

Halozyme Therapeutics

$16.28
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.43 (2.71%) Today
$0.00 (0.00%) As of 4:01 PM EDT after-hours

Why Robinhood?

You can buy or sell HALO and other stocks, options, ETFs, and crypto commission-free!

About HALO

Halozyme Therapeutics, Inc. Common Stock, also called Halozyme Therapeutics, is a biopharmaceutical company, which engages in research, development & commercialization of human enzymes and drug candidates. Read More It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

Employees
281
Headquarters
San Diego, California
Founded
1998
Market Cap
2.38B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
897.81K
High Today
$16.38
Low Today
$15.96
Open Price
$15.96
Volume
470.64K
52 Week High
$18.85
52 Week Low
$13.24

Collections

Therapy
Female CEOs
Health
Pharmaceutical
Biopharmaceutical
Biotechnology
Medical
Technology

HALO News

ReutersAug 15

Edited Transcript of HALO earnings conference call or presentation 6-Aug-19 8:30pm GMT

6

HALO Earnings

-$0.23
$0.13
$0.49
$0.85
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
-$0.14 per share
Actual
-$0.10 per share

More HALO News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.